All In Biotech

Investigational drug · Phase 3

ALK-001

Also called: C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Gildeuretinol acetate

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

5

Any phase or sponsor naming "ALK-001"

First trial start

2015

Aug 2015

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ALK-001", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Stargardt Disease
  • Stargardt Macular Degeneration
  • Stargardt Macular Dystrophy
  • Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

Approved drugs for the same conditions: Wet macular degeneration · Rare and genetic disease · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "ALK-001" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 11 on PubMed

Also in development for Stargardt Disease

  • OCU410STPhase 31 trial

    Ocugen · Stargardt Disease

  • AAVB-039Phase 21 trial

    AAVantgarde Bio Srl · Stargardt Disease

  • ACDN-01Phase 21 trial

    Ascidian Therapeutics, Inc · Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.